Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GCG | P01275 | 2/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403967 | 0.88 | MEN1 (0.39) | NTSR1MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL718170 | 0.88 | GCG (0.33) | NTSR1MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL718698 | 0.86 | KMT2A (0.32) | NTSR1MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL719036 | 0.82 | GCG (0.32) | GCG | |
| SCHEMBL719861 | 0.82 | SLC6A9 (0.41) | MEN1ALDH1A1KMT2AGCGSLC6A9 | |
| SCHEMBL718452 | 0.82 | MAPT (0.36) | NTSR1MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL720529 | 0.81 | GCG (0.35) | NTSR1GCGSLC6A9 | |
| SCHEMBL719881 | 0.81 | GCG (0.42) | GCG | |
| SCHEMBL718417 | 0.81 | GCG (0.36) | MEN1KMT2AGCG | |
| SCHEMBL720391 | 0.81 | GCG (0.40) | NTSR1MEN1ALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | NTSR1 1241/4885MEN1 444/4885ALDH1A1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.